This week, we highlight Moderna’s contract extension with Rovi, a recent report that indicates the global contract development and manufacturing organization (CDMO) market is expected to grow by over $8.65 billion by 2026, Robert Califf’s return as Food and Drug Administration commissioner, an artificial ... READ MORE >
5 things to know in life sciences: Week of Feb. 7, 2022
This week we highlight regulatory challenges for the United States and China; a softening of guidelines in the prescription of opioids; and record-breaking sales figures for Pfizer as it sees a more than 600% increase in vaccine revenue. Finally, we look at a new cartilage implant inspired by spiders and ... READ MORE >
Macroeconomic drivers for life sciences: Spring 2022 outlook
The three areas that middle market life sciences companies should pay specific attention to are supply chains, labor and capital markets. We anticipate a decreased appetite from private investors to pay high company valuations, but an uptick in the number of life sciences startups. This presents an ... READ MORE >
5 things to know in life sciences: Week of Jan. 31, 2022
This week, we highlight a breakthrough tubeless insulin pump which received Food and Drug Administration clearance. We also look at a telehealth pharmacy booming during the pandemic, potential breakthroughs in neurovascular research, the disparity of Asian scientists’ contributions and recognition in ... READ MORE >
5 things to know in life sciences: Week of Jan. 24
This week we look at the ethical challenges facing neuroscientists as they recruit patients for clinical research. We also look at a ride share company entering the health care space and what it may mean for clinical trial recruitment, CBD as a prevention measure for COVID-19, deltacron and ... READ MORE >
5 things to know in life sciences: Week of Jan. 17, 2022
This week, we look at antimicrobial-resistant diseases, their toll on health systems globally and the need for new treatments. We also feature the continued delays in Food and Drug Administration inspections, the demand for decentralized trials, as well as medtech's initial public offerings and their ... READ MORE >
5 things to know in life sciences: Week of Jan. 10
This week we highlight a flood of studies and approvals with a focus on leveraging new technologies, data and gene sequencing to increase patient care. While the life sciences industry has always been on the forefront of innovation, we are now seeing the various components of the ecosystem come together ... READ MORE >
5 things to know in life sciences: Week of Jan. 3
This week we explore a partnership between a large biopharma and a machine learning startup. In addition, we look at a non-commercial approach to address the global COVID-19 vaccine shortage, a major mRNA-focused acquisition, a temporary pause on factory inspections, and finally, 55 new drug approvals in ... READ MORE >
Five things to know in life sciences: Week of Dec. 13
This week, Pfizer announced another major investment in manufacturing capacity in the United States. Its investment in a new facility is focused on tackling the unique challenges in manufacturing gene therapies. We also look at the possibility of replacing glasses with eye drops, crowdsourcing cancer ... READ MORE >
Five things to know in life sciences: Week of Dec. 6
This week a new investment fund is starting that is focused on the modest goal of extending human life. We also look at new leadless pacemakers, using illustrated stories to make the complexity of clinical trials easier for patients to understand, and studying the common cold as a window into future ... READ MORE >